| Analysis | Incremental QALYs vs ST | Incremental costs vs ST | INMB at £20K(a) | Probability most CE option | Rank (95% CI) |
|---|---|---|---|---|---|
| ST | £0 | 0% | 3 (2, 3) | ||
| ICS+PCS | 0.000 | £420 | -£423 | 0% | 4 (4, 4) |
| PCS | 0.000 | -£108 | £113 | 40% | 2 (1, 3) |
| TXA | 0.000 | -£169 | £173 | 60% | 1 (1, 2) |
Abbreviations: CI = confidence intervals; ICS = intra-operative cell salvage; INMB = incremental net monetary benefit; PCS = post-operative cell salvage; QALYs = quality adjusted life years; ST = standard treatment; TXA = tranexamic acid
INMB = NMB intervention A – NMB ST; Highest INMB = most cost-effective option at a £20,000 per QALY threshold; a negative INMB means that ST is more cost-effective than this option.
From: 6, Alternatives to blood transfusion for patients having surgery: Cell salvage and tranexamic acid
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.